UK Trade & Investment and British Consul-General Welcome Leading Nanotechnology Company Oxonica to Bay Area; Reception at Official Residence Follows Nanotag-Enabled Lateral Flow Product Showcase
In his welcoming remarks, Martin Uden, British Consul-General, San Francisco, said, "The US and UK have long had important ties in science and technology, and it is exciting to see this continuing into the area of nanotechnology. With its best-of-breed products already available in Europe and Asia, Oxonica has established itself as a global presence, perhaps the first truly global nanotechnology company, and certainly the pre-eminent nanotechnology company in the UK. In coming to Silicon Valley, Kevin Matthews, David Browning and the rest of the Oxonica team have proved themselves to be visionary business leaders. I welcome Oxonica, and look forward to working with them to grow their business opportunity."
“Joining a UK-based company has created a special opportunity for Nanoplex's technologies”
"We thank UK Trade & Investment and the British Consulate for this wonderful welcome, and are excited to be in the Bay Area," said Kevin Matthews, CEO of Oxonica plc. "By acquiring Nanoplex Technologies, we have established a major business and technology foothold in the US, and positioned the company to rapidly enter the clinical diagnostics market. Our goal is to be the global leader in healthcare technologies enabled by nanomaterials, and the Nanoplex acquisition is a significant step towards that goal."
"Joining a UK-based company has created a special opportunity for Nanoplex's technologies," said Michael Natan, formerly founder of Nanoplex and now president of Oxonica Inc. "An established and successful infrastructure for the development and commercialization of nanomaterial-based products will be vital to the success of Oxonica Inc.'s healthcare business. The support that the British Consulate has shown, both for this acquisition and for our business going forward, has been rewarding."
Oxonica Inc. was formed by Oxonica plc's acquisition of Nanoplex Technologies in February 2006. When the acquisition closed earlier this month, Nanoplex was merged with Oxonica Healthcare and renamed Oxonica Inc. with Michael Natan as president.
About Oxonica Inc.
Oxonica Inc. is a leading developer of commercial nanotechnology-enabled products for global health and personal care markets. Established in 2005 by the merger of Oxonica Healthcare and Nanoplex Technologies, Oxonica Inc. is actively engaged in developing transformational detection technologies that will enable a new generation of standardized ultra-sensitive multiplexed diagnostic tools for applications from drug development through point of care. The company's commercialized product portfolio includes Optisol(TM), a powerful UVA and UVB protection system for quality sunscreens and anti-aging products. Oxonica Inc. is headquartered in Mountain View, CA. www.oxonica.com
About Oxonica plc
Oxonica is one of the leading European nanomaterials groups with products already launched into international markets. It was spun-out from Oxford University in 1999 and currently employs 54 professional staff. Oxonica's mission is to develop innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. The company has three operating divisions: Oxonica Energy, Oxonica Healthcare and Oxonica Materials.
Commercialized products are:
Envirox(TM) Fuel Borne Catalyst - a fuel borne nanocatalyst for diesel engines which reduces fuel consumption with savings of 5-10% and reduces particulate emissions by up to 15%. The product has already been adopted by Stagecoach Group in the UK and is distributed by Veridium Technology Inc. to petroleum companies in the Philippines for use in a premium diesel.
Optisol(TM) UV Absorber - a photostable UV absorber that provides enhanced and longer lasting protection against UVA in sun-care and anti-ageing products. Optisol(TM) also reduces the formation of free radicals produced from exposure to the sun and which are implicated in premature skin ageing. Boots Group plc was the first to incorporate Optisol(TM) in their new Soltan Facial Sun Defense Cream for 2005.
In addition, Oxonica is working to generate a range of future product applications. These include additional fuel saving additives, biomarker detection technology for the clinical and life science diagnostics markets, further UV protection applications, including tailoring the Optisol(TM) product in the cosmetics markets, and new products for plastics and coatings, transparent conducting films and security markers.
Optisol(TM) and Envirox(TM) are trademarks of Oxonica.
For further information, please visit www.oxonica.com.
About UK Trade & Investment
UK Trade & Investment is the British Government's international business development agency, supporting companies in the UK doing business internationally and overseas enterprises seeking to establish a market footprint in the UK. The integrated services offered by UK Trade & Investment bring together a network of business sector specialists and support teams in over 200 British embassies and Foreign and Commonwealth Office (FCO) posts overseas, as well as key experts in government departments across the UK.
As a government agency, UK Trade & Investment is uniquely positioned to offer expanding companies access to a growing network of global business advisors and bespoke market entry intelligence and guidance on operational issues. With its government connections, in-depth knowledge of UK regional business, ties to leading institutions, science and technology resources, as well as its global network, UK Trade & Investment is a unique strategic resource for companies that want to operate in the number one business location in Europe. For more information visit: www.uktradeinvestusa.com